Research and Development

Showing 15 posts of 9615 posts found.

Logos

AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015 Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

Takeda gets European MAA approval for ixazomib

August 21, 2015 Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma

Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
novartis

Novartis buys rights to GSK MS drug for up to $1 billion

August 21, 2015 Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab

Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
lilly_corporate_hq

Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks

August 21, 2015 Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs

Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …
sun_pharma_hq

Sun Pharma gets FDA approval for acne treatment

August 21, 2015 Medical Communications, Research and Development, Sales and Marketing Sun Pharma. acne treatments, drug approvals

The FDA has approved Sun Pharma’s new acne treatment, Ximino.The Ximino (minocycline hydrochloride) extended-release capsules, which will be available in …
Advanced melanoma

Novartis and Merck skin cancer drugs move through pipeline

August 20, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib

Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Sprout sign

FDA approves ‘female viagra’

August 19, 2015 Research and Development, Sales and Marketing Addyi, FDA, HSDD, Sprout, Sprout Pharmaceuticals, flibanserin, hypoactive sexual desire disorder

The FDA has approved Sprout Pharmaceuticals’ Addyi, a controversial libido-enhancing drug for women that has been dubbed the ‘female viagra’. …
BioScience Nottingham

Nottingham receives go ahead for new £30m life science facility

August 19, 2015 Manufacturing and Production, Research and Development BioCity Nottingham, R&D

Hundreds of pharma jobs are expected to be created in Nottingham after the construction of a new £30 million life …
car_t-cells

Kite Pharma says trial death was unrelated to KTE-C19

August 18, 2015 Medical Communications, Research and Development CAR-T, cinical trials, kite pharma, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma

Kite has confirmed last week’s rumours that a patient had died during its Phase I/II trial for the KTE-C19 non-Hodgkin’s …
ALS research

Biogen collaborates with ALSA and Columbia University on genomic-based ALS treatments

August 18, 2015 Research and Development

Biogen, the ALS Association and Columbia University Medical Center (CUMC) have announced a new collaboration aimed at better understanding the differences …
Chest x ray

Roche lung cancer therapy succeeds in mid-stage trial

August 17, 2015 Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer

Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
Keytruda image

Merck in immuno-oncology collaboration with major cancer research centre

August 14, 2015 Research and Development Cancer, Merck, keytruda, oncology

Merck is teaming up with the University of Texas to evaluate Merck’s anti-PD-1 therapy, Keytruda, in combination with other treatmentsA team …

Abbvie and Roche report success in Phase II leukaemia trial

August 13, 2015 Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax

AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
The Gateway to Local Adoption Series

Latest content